Despite bumpy launches for two of its key generics in the US – rivals to Amarin’s Vascepa (icosapent ethyl) and GlaxoSmithKline’s Advair (fluticasone/salmeterol) – and the pressures of the COVID-19 pandemic, Hikma has nevertheless managed to deliver solid growth in 2020, with a double-digit ramp-up in operating profit outpacing a 6% turnover increase on the back of solid performances across its three key business segments.
Hikma Proves Resilient In 2020 Despite Some Bumpy Launches
Rivals To Advair And Vascepa Suffer From Delays And API Scarcity
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
